By the same authors

From the same journal

The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective

Research output: Contribution to journalArticle

Published copy (DOI)


  • A Griffiths
  • N Paracha
  • A Davies
  • N Branscombe
  • M R Cowie
  • M Sculpher


Publication details

DatePublished - 14 Mar 2014
Issue number13
Pages (from-to)1031-1036
Original languageEnglish


Ivabradine, a specific heart rate lowering therapy, has been shown in a randomised placebo-controlled study, Systolic HF Treatment with the If Inhibitor Ivabradine Trial (SHIfT), to significantly reduce the composite end point of cardiovascular death and hospitalisation for worsening heart failure (HF) in patients with systolic HF who are in sinus rhythm and with a heart rate ≥70 bpm, when added to optimised medical therapy (HR: 0.82, 95% CI 0.75 to 0.90, p

Discover related content

Find related publications, people, projects, datasets and more using interactive charts.

View graph of relations